Hi WBA That's $AUD 8.5m. These issues caught my attention.*...

Hi WBA

That's $AUD 8.5m. These issues caught my attention.


* Starpharma will license certain intellectual property (“IP”) to Petalion as required for the research, development, manufacture
and commercialisation of this potential new therapeutic and, in exchange, will receive an equity holding of 22.5% in Petalion.

SPL has a entire stable of dendrimer-drug conjugate therapies. Which of these has been selected for this IP agreement is not specified. How many other
dendrimer-drug conjugate therapies have been left on the shelf, for other similar IP agreements, is also not specified.

* Starpharma will license the IP to Petalion on an exclusive basis for a mutually agreed target. Target not specified. What happens after that target is reached is also not specified. This to me suggests a new replacement IP agreement in the event of this happening.

* Starpharma will also provide R&D services to Petalion on a fee for service basis. An additional income stream important considering cash-burn issues.

I find that this announcement is an important first step to turn this company around. Why?

Just my opinions.

- I think that Petalion would have cherry-picked the therapies that were most likely to get to commercialisation stage So more than likely the therapies no longer patent protected being replicated by various pharma companies, but still having serious side effects. With Petalion targeting to offer the same product with dramatically reduced side effects by using the dendrimer IP. Makes sense to me.

- Petalion is a UK based company. As we have seen with Viraleze being available in the UK, Europe and other nations around the world, it may bypass the roadblocks the FDA throws up in the commercialisation process. I think a very important issue as far a speed to commercialisation.

- Finally to the other companies currently sitting on the sidelines about actioning IP agreements with SPL. There may arise the issue of FOMO on dendrimer products as they begin to disappear off the shelf.

Some hope for SPL yet. I like the style of this new CEO.

DYOR

cheers Lies













Starpharma will also provide R&D services to Petalion on a fee for service basis. Income stream.